Norges Bank Vanda Pharmaceuticals Inc. Transaction History

Norges Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.91 - $6.5 $449,650 - $747,500	115,000 New	115,000 $649,000
Q4 2023 Feb 09, 2024	BUY	$3.38 - $4.58 $388,700 - $526,700	115,000 New	115,000 $485,000
Q3 2023 Nov 13, 2024	BUY	$4.28 - $6.57 $492,200 - $755,550	115,000 New	115,000 $496,000
Q1 2023 May 15, 2024	BUY	$6.18 - $7.99 $982,620 - $1.27 Million	159,000 New	159,000 $1.08 Million
Q4 2022 Feb 14, 2023	BUY	$6.87 - $10.96 $1.09 Million - $1.74 Million	159,000 New	159,000 $1.18 Million

157

44.9M

165K

33.6K

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $249M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.